GNI Group Ltd. (JP:2160)
:2160
Want to see JP:2160 full AI Analyst Report?
2160 Stock Chart & Stats
¥3370.00
¥50.00(1.64%)
At close: 4:00 PM EST
¥3370.00
¥50.00(1.64%)
Day’s Range― - ―
52-Week Range¥2,112.00 - ¥4,410.00
Previous CloseN/A
Volume492.20K
Average Volume (3M)969.16K
Market Cap
¥168.41B
Enterprise Value¥152.43B
Total Cash (Recent Filing)¥21.10B
Total Debt (Recent Filing)¥5.37B
Price to Earnings (P/E)―
Beta1.17
Next Earnings
May 15, 2026EPS Estimate
-2.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-74.44
Shares Outstanding55,767,544
10 Day Avg. Volume1,104,200
30 Day Avg. Volume969,156
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)2.52
Price to Sales (P/S)4.71
P/FCF Ratio-46.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥3,800.00Price Target Upside12.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)53.4
Revenue Forecast (FY)¥30.85B
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthLow leverage and materially higher equity provide durable financial resilience, reducing refinancing risk and supporting continued R&D and commercial investment. This balance sheet flexibility improves the company’s runway and bargaining power in partnerships over the next several quarters.
High Gross MarginsSustained high gross margins indicate strong product economics and pricing power that can absorb elevated operating costs or fund reinvestment. Margins are a structural advantage for long-term profitability if revenue stabilizes, supporting scalable profitability once operating leverage returns.
Robust Pipeline & PartnershipsA diversified pipeline focused on respiratory and fibrotic therapies plus licensing and collaboration revenue channels provide multiple durable growth levers. Partnerships can de-risk development, accelerate commercialization, and create non-linear upside versus single-product models over the medium term.
Bears Say
Persistent Negative Cash FlowTwo consecutive years of negative operating and free cash flow signal the business is not self-funding, elevating financing and execution risk. Persistent cash burn can force dilutive capital raises or restrict investment in trials and commercialization, weakening long-term strategy execution.
Profitability Swing To LossesA sharp deterioration to meaningful losses undermines internal funding capacity and raises questions about cost control or one-off charges. Restoring sustainable operating profitability will be required to support R&D and commercialization without repeated external financing over the medium term.
Volatile Revenue & Earnings VisibilityHistoric volatility in revenue and earnings reduces predictability for planning trials, manufacturing scale-up, and partner deals. In biotech, such variance increases partner and investor scrutiny, complicates budgeting and may pressure negotiation leverage for licensing or commercialization agreements.
GNI Group News
2160 FAQ
What was GNI Group Ltd.’s price range in the past 12 months?
GNI Group Ltd. lowest stock price was ¥2112.00 and its highest was ¥4410.00 in the past 12 months.
What is GNI Group Ltd.’s market cap?
GNI Group Ltd.’s market cap is ¥168.41B.
When is GNI Group Ltd.’s upcoming earnings report date?
GNI Group Ltd.’s upcoming earnings report date is May 15, 2026 which is in 11 days.
How were GNI Group Ltd.’s earnings last quarter?
GNI Group Ltd. released its earnings results on Feb 13, 2026. The company reported -¥74.44 earnings per share for the quarter, missing the consensus estimate of ¥224.642 by -¥299.082.
Is GNI Group Ltd. overvalued?
According to Wall Street analysts GNI Group Ltd.’s price is currently Undervalued.
Does GNI Group Ltd. pay dividends?
GNI Group Ltd. does not currently pay dividends.
What is GNI Group Ltd.’s EPS estimate?
GNI Group Ltd.’s EPS estimate is -2.74.
How many shares outstanding does GNI Group Ltd. have?
GNI Group Ltd. has 55,767,544 shares outstanding.
What happened to GNI Group Ltd.’s price movement after its last earnings report?
GNI Group Ltd. reported an EPS of -¥74.44 in its last earnings report, missing expectations of ¥224.642. Following the earnings report the stock price went down -3.49%.
Which hedge fund is a major shareholder of GNI Group Ltd.?
Currently, no hedge funds are holding shares in JP:2160
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GNI Group Ltd.
GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial phase II and pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase II clinical trial for the treatment of liver fibrosis; and F573 that is in pre-clinical phase for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.
2160 Stock 12 Month Forecast
Average Price Target
¥3,800.00
▲(12.76% Upside)
Technical Analysis
Peptidream
―
SanBio Co
―
Sosei Group
―
Takara Bio Inc.
―
Japan Tissue Engineering Co., Ltd.
―
Options Prices
Currently, No data available
---